Xuhong Min

1.8k total citations
8 papers, 39 citations indexed

About

Xuhong Min is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Xuhong Min has authored 8 papers receiving a total of 39 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Xuhong Min's work include Lung Cancer Treatments and Mutations (4 papers), Lung Cancer Diagnosis and Treatment (3 papers) and Lung Cancer Research Studies (3 papers). Xuhong Min is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Lung Cancer Diagnosis and Treatment (3 papers) and Lung Cancer Research Studies (3 papers). Xuhong Min collaborates with scholars based in China. Xuhong Min's co-authors include Ao Li, Haichun Li, Minghui Wang, Biao Song, Jianxing He, Xingxiang Xu, Feng Luo, Yunru Chen, Yuping Gong and Yongqiang Yu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Xuhong Min

7 papers receiving 38 citations

Peers

Xuhong Min

PRM

RNMI

ONCOL

AI

CVPR

Biqing Zheng China

Alexandra Renn United Kingdom

Haythem Ali United States

Adam Casson United States

Hare Krishna India

Y. M. Goh South Korea

Julian Viret United States

Ananth Reddy Bhimireddy United States

Yangsibo Huang United States

Baptiste Laurent France

Biqing Zheng China

Xuhong Min

17 ×0.7

PRM

28 ×1.1

RNMI

19 ×1.6

ONCOL

8 ×0.7

AI

5 ×1.3

CVPR

Citations per year, relative to Xuhong Min Xuhong Min (= 1×) peers Biqing Zheng

Countries citing papers authored by Xuhong Min

Since Specialization

Citations

This map shows the geographic impact of Xuhong Min's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xuhong Min with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xuhong Min more than expected).

Fields of papers citing papers by Xuhong Min

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xuhong Min. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xuhong Min. The network helps show where Xuhong Min may publish in the future.

Co-authorship network of co-authors of Xuhong Min

This figure shows the co-authorship network connecting the top 25 collaborators of Xuhong Min. A scholar is included among the top collaborators of Xuhong Min based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xuhong Min. Xuhong Min is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Cheng, Ying, Lin Wu, Yong Fang, et al.. (2024). Abstract CT248: Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial. Cancer Research. 84(7_Supplement). CT248–CT248. 5 indexed citations

2.

Cheng, Ying, Liang Han, Lin Wu, et al.. (2024). Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study.. Journal of Clinical Oncology. 42(16_suppl). 8100–8100.

3.

Cheng, Ying, Caicun Zhou, Xuhong Min, et al.. (2023). 84P Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC): 3-year update of the phase III CAPSTONE-1 study. Immuno-Oncology Technology. 20. 100556–100556. 2 indexed citations

4.

Li, Haichun, et al.. (2022). Reconstruction-Assisted Feature Encoding Network for Histologic Subtype Classification of Non-Small Cell Lung Cancer. IEEE Journal of Biomedical and Health Informatics. 26(9). 4563–4574. 17 indexed citations

5.

Lu, Shaoming, Yandan Yao, Jianxing He, et al.. (2022). 8MO The efficacy and safety of TQ-B3101 monotherapy in the first-line treatment in patients with ROS1-positive non-small cell lung cancer. Annals of Oncology. 33. S31–S31. 2 indexed citations

6.

Min, Xuhong, et al.. (2021). Urban–Rural Differences in Clinical Characteristics of Prostate Cancer at Initial Diagnosis: A Single-Center Observational Study in Anhui Province, China. Frontiers in Oncology. 11. 704645–704645. 1 indexed citations

7.

Song, Biao, et al.. (2021). AIR-Net: A novel multi-task learning method with auxiliary image reconstruction for predicting EGFR mutation status on CT images of NSCLC patients. Computers in Biology and Medicine. 141. 105157–105157. 9 indexed citations

8.

Zhang, L., Hongyun Zhao, Zhiyuan Zhang, et al.. (2020). LBA50 ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706). Annals of Oncology. 31. S1181–S1181. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact